THE CIGNA GROUP AND SUBSIDIARIES (FORMERLY CIGNA CORPORATION AND SUBSIDIARIES)

Lobbying for THE CIGNA GROUP AND SUBSIDIARIES (FORMERLY CIGNA CORPORATION AND SUBSIDIARIES)

Filing 2nd Quarter - Amendment

2nd Quarter (Apr 1 - June 30) 2025 · District of Columbia · House · Senate · $1,930,000.00 expenses · posted Oct 20, 2025

Official filing document

Bills named in this filing 13

HR 4189
To direct the Secretary of the Navy to recognize certain aspects of the National Navy UDT-SEAL Museum in Fort Pierce, F…
S 2016
Chugach Alaska Land Exchange Oil Spill Recovery Act of 2025
S 864
HELP Copays Act
HR 247
Health Care Affordability Act of 2025
HR 1
An act to provide for reconciliation pursuant to title II of H. Con. Res. 14.
HR 2041
Hidden Fee Disclosure Act of 2025
HR 2214
DRUG Act
S 526
Pharmacy Benefit Manager Transparency Act of 2025
S 1040
Drug Competition Enhancement Act
S 1041
Affordable Prescriptions for Patients Act
S 1542
DRUG Act
HR 5378
Lower Costs, More Transparency Act
S 1339
Pharmacy Benefit Manager Reform Act

Lobbying activity 5

Labor Issues/Antitrust/Workplace

Issues related to competition in the health care marketplace.

Medicare/Medicaid

P.L. 117-169, the Inflation Reduction Act of 2022; H.R. 4189/S. 2016, The Creating Opportunities Now for Necessary and Effective Care Technologies (CONNECT) for Health Act of 2023; Issues related to transparency and prior authorization.

Health Issues

S. 864/H.R. 247, the Health Care Affordability Act of 2025 and issues relating to extension of Enhanced Advanced Premium Tax Credits (EAPTCs) including in the American Rescue Plan Act (ARPA) and the Inflation Reduction Act (IRA); Issues related to P.L.119-21 (H.R. 1), the One Big Beautiful Bill Act, and budget reconciliation; Issues related to H.R. 2041, the Hidden Fee Disclosure Act of 2025.

Defense

Pharmacy issues related to the National Defense Authorization Act, FY2026.

Pharmacy

S. 1542/H.R.2214, the DRUG Act; H.R. 5378 Lower Costs, More Transparency Act; S. 1339, Pharmacy Benefit Manager Reform Act; S.526, Pharmacy Benefit Manager Transparency Act; S. 1040, The Drug Competition and Enhancement Act; S. 1041, The Affordable Prescriptions for Patients Act; Issues related to the specialty drug market.

Source: federal Lobbying Disclosure Act filing. Bills are parsed from the activity descriptions.